Author

Alexander T. Nguyen

University of Colorado AnschutzORCID 0009-0004-1108-2176Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Approach:genetic perturbation / CRISPR· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

Anthony J. SaviolaiD· 2 shared Brooke NeupertiD· 2 shared Diemmy NguyeniD· 2 shared Jacob GadwaiD· 2 shared Khalid N.M. AbdelazeemiD· 2 shared Laurel B. DarraghiD· 2 shared Michael W. KnitziD· 2 shared Nicholas A. OlimpoiD· 2 shared

Activity by Year

2024-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

Anthony J. SaviolaORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Divergent response to radio-immunotherapy is defined by intrinsic features of the tumor microenvironment

Jacob Gadwa, Justin Yu, Miles Piper, Michael W. Knitz, Laurel B. Darragh, Nicholas A. Olimpo, Sophia Corbo, Jessica I. Beynor, Brooke Neupert, Alexander T. Nguyen, Chloe A. Hodgson, Diemmy Nguyen, Khalid N.M. Abdelazeem, Anthony J. Saviola, Laurène Pousse, , Sana D. Karam

This study shows that combining immunotherapies can lead to divergent tumor responses based on the tumor microenvironment, with Treg depletion reversing progression in pancreatic cancer.

Journal for ImmunoTherapy of Cancer · Jan 1, 2025Peer-reviewedImmunology

Manipulating the EphB4-ephrinB2 axis to reduce metastasis in HSNCC

Khalid N.M. Abdelazeem, Diemmy Nguyen, Sophia Corbo, Laurel B. Darragh, Mike W. Matsumoto, Benjamin Van Court, Brooke Neupert, Justin D. Yu, Nicholas A. Olimpo, Douglas Grant Osborne, Jacob Gadwa, Richard B. Ross, Alexander T. Nguyen, Shilpa Bhatia, Mohit Kapoor, , Sana D. Karam

This study shows that targeting the EphB4-ephrinB2 axis with engineered ligands reduces metastasis in HNSCC by modulating tumor microenvironment and immune responses.

Oncogene · Nov 3, 2024Peer-reviewedCancer Biology